Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Nojiri, S
Busetto L, Bettini S, Makaronidis J, Roberts CA, Halford JCG, Batterham RL
The New England journal of medicine, 387(3), 205216
Early studies in obese individuals showed some reductions in body fat mass, but findings are not consistent across trials: In one clinical trial, AOD9604 did not demonstrate statistically significant weight loss compared to placebo, suggesting its fat-burning effects may be modest without lifestyle intervention (summary of trials)
On the other hand, a person with more muscle mass may require a slightly longer needle for an intramuscular shot to reach the muscle effectively
Those who switched to placebo regained approximately 7% of their body weight, whereas those continuing semaglutide treatment lost an additional 3%
